

CAP Cancer Protocols Summary of Changes September 2025

	Protocol	Protocol Version Number	eCP Version Number	Summary of Changes
1	Central Nervous System	V 1.0.0.1	V 1.000.011	<ul style="list-style-type: none"> eCP only metadata and eCP only explanatory note electronic link updates
2	Colon Resection	V 4.4.0.1	V 3.009.011	<ul style="list-style-type: none"> Typographical update to Multiple Primary Sites display item
3	GYN Biomarker	V 1.3.0.0	V 1.003.001	<ul style="list-style-type: none"> TEST(S) PERFORMED section re-labeled as IMMUNOHISTOCHEMICAL TEST(S) PERFORMED for clarity HER2 In Situ Hybridization Testing Status added as a required element for reporting Equivocal (score 2+) protein overexpression in HER2 Status for Trastuzumab Use MLH1 Promoter Methylation Analysis Status added as a required element for reporting Loss of nuclear expression of MLH1 and PMS2 in Immunohistochemistry (IHC) Interpretation for Mismatch Repair (MMR) Proteins All immunohistochemical tests made optional (previously required) Image Analysis question modified Optional Tests Pending question response added in ADDITIONAL TESTS section
4	Hematologic - Myeloid and Mixed / Ambiguous Lineage Neoplasms	V 1.1.0.1	V 1.001.011	<ul style="list-style-type: none"> eCP only metadata and eCP only explanatory note electronic link updates
5	Hematologic - Plasma Cell Malignancies	V 1.0.0.1	V 1.000.011	<ul style="list-style-type: none"> eCP only metadata and eCP only explanatory note electronic link updates
6	Hematologic - Precursor and Mature Lymphoid Malignancies	V 1.0.0.1	V 1.000.011	<ul style="list-style-type: none"> eCP only metadata and eCP only explanatory note electronic link updates
7	IHC General Biomarker	V 1.2.0.0	V 1.003.001	<ul style="list-style-type: none"> Addition of optional Cold Ischemic Time, Fixative, and Fixation Time, Membranous Staining Intensity questions Addition of “Internal control cells present: expected immunoreactivity” and “Internal controls present: no immunoreactivity of either tumor cells or internal controls” answers to HER2 IHC Methods and Ki-67 IHC Methods Removal of the parenthetical statement (indeterminate) for “Cannot be determined” answers
8	Lung Biomarker	V 2.2.0.0	V 2.002.001	<ul style="list-style-type: none"> Updates to EGFR, ALK, ROS1, RET, BRAF, NTRK, and PD-L1 sections Addition of NRG1 section Addition of optional Specify Fusion Partner question to ROS1, RET NTRK1, NTRK2, and NTRK3 Molecular Methods Addition of BRAF:p.V600K, BRAF:p.V600R, and BRAF:p.V600D answers to BRAF Mutational Analysis question Addition of specific PD-L1 markers to include PD-L1 22c3, PD-L1 228-8, PD-L1 SP142, and PD-L1 SP263

CAP Cancer Protocols Summary of Changes September 2025

	Protocol	Protocol Version Number	eCP Version Number	Summary of Changes
9	Lung Resection Accreditation Change	V 5.1.0.0	V 4.001.001	<ul style="list-style-type: none"> Invasive Tumor Size and Size of In Situ Carcinoma in Centimeters (cm) made conditionally reported eCP only metadata updates to Number of Intrapulmonary Lymph Nodes (within the same lobe), Number of Intrapulmonary Lymph Nodes (in different lobes), and Number of Distant Metastases
10	Retinoblastoma Accreditation Change	V 4.2.0.0	V 3.003.001	<ul style="list-style-type: none"> pTNM Classification update Removal of “Distance from Anterior Edge of Tumor to Limbus at Cut Edge” and “Distance from Posterior Margin of Tumor Base to Edge of Optic Disc” optional questions Addition of optional SPECIAL STUDIES section eCP only metadata and eCP only explanatory note electronic link updates
11	Uveal Melanoma Res Accreditation Change	V 4.2.0.0	V 3.003.001	<ul style="list-style-type: none"> pTNM Classification update “Gene Expression Profile (GEP)” question update and addition of optional “Other Special Studies (specify)” question response in SPECIAL STUDIES section eCP only metadata and eCP only explanatory note electronic link updates